Cytori Receives FDA Orphan Drug Designation For ATI-1123 Candidate

(RTTNews) - Cytori Therapeutics (CYTX) announced it received FDA orphan drug designation for its ATI-1123 chemotherapy drug product candidate, an albumin-stabilized pegylated liposomal docetaxel, for the treatment of small cell lung cancer.

Cytori is also exploring the development of ATI-1123 to address the shortcomings of docetaxel, a workhorse chemotherapy drug. A U.S. Phase 1 clinical study of ATI-1123 has been completed. Of the 29 patients in the study with cervical, gastric, melanoma, non-small cell lung, ovarian, pancreatic, prostate, thyroid, urachal and uterine cancers, 82% demonstrated a clinical benefit with ATI-1123.